Melanotan II vs PTD-DBM.

Melanotan II (MT-II) is a synthetic, cyclic heptapeptide analog of the natural hormone alpha-melanocyte-stimulating hormone (alpha-MSH). It was developed at the University of Arizona in the late 1980s and 1990s as part of a program designing protease-resistant "superpotent" melanotropins; the related linear analog melanotan I became the approved drug afamelanotide (Scenesse). Unlike afamelanotide, Melanotan II itself was never approved as a medicine and today circulates almost exclusively as an unlicensed product sold online for cosmetic "tanning" and as a libido agent.

PTD-DBM is a synthetic, cell-permeable peptide whose name stands for "Protein Transduction Domain–Dishevelled Binding Motif." It fuses a short protein-transduction (cell-penetrating) domain to a peptide sequence that mimics the Dishevelled-binding region of the protein CXXC5, allowing it to act as a competitive decoy. It was created as a research tool to manipulate Wnt/β-catenin signaling in skin and hair-follicle biology and is not a drug, nutritional product, or approved therapeutic.

Melanotan II is a non-selective agonist of the melanocortin receptor family, binding MC1R, MC3R, MC4R and MC5R rather than selectively targeting MC1R. Activation of MC1R on cutaneous melanocytes stimulates the cAMP pathway and shifts melanin synthesis toward darker eumelanin, producing skin darkening that, unlike a UV tan, can occur with reduced sun exposure. Its central effects on sexual arousal and appetite are attributed mainly to MC4R (with possible MC3R contribution) in the hypothalamus and related circuits, while nausea, flushing and yawning also arise from this broad central melanocortin activation. The cyclic lactam structure makes it markedly more resistant to enzymatic degradation and more potent and longer-acting than native alpha-MSH.

CXXC-type zinc finger protein 5 (CXXC5) is a negative-feedback regulator of canonical Wnt/β-catenin signaling that works by binding the scaffolding protein Dishevelled (Dvl), preventing Dvl from transmitting the Wnt signal. PTD-DBM carries a sequence that imitates the Dvl-binding motif, so it competitively occupies that interface and disrupts the CXXC5–Dvl interaction. Freed from CXXC5 inhibition, Dvl can stabilize β-catenin, which in turn drives transcriptional programs associated with the anagen (growth) phase of the hair cycle, dermal-papilla activity, and epithelial proliferation in wounds. In the founding work this de-repression of Wnt signaling was the proposed basis for both accelerated hair regrowth and wound-induced hair neogenesis (de novo follicle formation within healing skin).

Human data on Melanotan II is limited to small, early-phase academic studies and a large body of case reports; no Phase 2/3 program was ever completed and it has never been tested in large controlled trials. The best-documented human work is on erectile function: a 1998 double-blind, placebo-controlled crossover study in men with psychogenic erectile dysfunction (Wessells et al., J Urol) and a 2000 study in men with organic erectile dysfunction (Urology) reported that subcutaneous Melanotan II initiated erections, accompanied by frequent nausea and yawning. Its tanning rationale rests on MC1R pharmacology and on the broader melanotan development program (Hadley et al., 1998), but rigorous controlled efficacy/safety data for cosmetic tanning in humans is essentially absent. Most contemporary human evidence comes from adverse-event case reports, including systemic toxicity with rhabdomyolysis (Clinical Toxicology, 2012) and dermatologic changes, so claims of benefit substantially outrun the controlled-trial evidence.

The evidence base is preclinical. The foundational study (Lee et al., J Invest Dermatol 2017, PMID 28595998) reported that CXXC5 is elevated in balding human scalp and that disrupting the CXXC5–Dishevelled interaction with the competing peptide activated Wnt/β-catenin signaling, accelerated hair regrowth, and promoted wound-induced hair neogenesis in mice; effects were enhanced when combined with valproic acid (a GSK3β-modulating Wnt activator), and Cxxc5-knockout mice phenocopied the benefit. Earlier work established CXXC5 itself as a negative regulator of cutaneous wound healing (Lee et al., J Exp Med 2015, PMID 26056233), and a 2023 study (Cells, PMID 36831222) linked CXXC5 to DHT/PGD2-driven androgenetic alopecia, supporting the target's relevance. The same Yonsei group later advanced a small-molecule Wnt activator, KY19382 (Br J Pharmacol 2021, PMID 33751552), as a more drug-like successor. Critically, no human clinical trials of PTD-DBM have been published; human relevance rests on cultured human follicle cells and on the observation of elevated CXXC5 in bald scalp, not on controlled efficacy data in people.

Commonly reported short-term effects in humans include nausea, vomiting, facial flushing, spontaneous yawning and stretching, appetite suppression, darkening of existing moles, and spontaneous erections or priapism in men. More serious documented harms from unregulated use appear in case reports: rhabdomyolysis and systemic toxicity, and a recurring concern about changes to melanocytic naevi (new and darkening moles, atypical naevi) with multiple published cases of melanoma reported in users, though causality has not been established and confounding by concurrent UV/tanning-bed exposure is a major limitation. Because the product is unlicensed and typically self-injected from non-pharmaceutical sources, contamination, mislabeling, dosing errors and sterility problems are additional, poorly quantified risks. This entry intentionally gives no doses or protocols; anyone considering use should consult a clinician, and dermatology bodies advise against use.

There are no published human safety data, pharmacokinetics, or toxicology studies for PTD-DBM; it has been used only as an experimental reagent in animal and cell-culture models, so its safety profile in humans is genuinely unknown. As a cell-penetrating peptide that broadly de-represses Wnt/β-catenin signaling, a theoretical concern is that sustained or systemic Wnt activation could have off-target effects on tissues where the pathway influences proliferation, though no such outcomes have been characterized for this peptide specifically. Material sold online is research-use-only, is not produced or tested to pharmaceutical quality standards, and purity, sterility, and identity cannot be assumed. Anyone encountering PTD-DBM should treat it strictly as an unapproved experimental compound.

Melanotan II is not approved by the FDA or any major regulator for any indication and is not legally marketed as a medicine; products sold online are unlicensed. Regulators including the US FDA, the UK MHRA and Australia's TGA have issued consumer warnings against it. The distinct linear analog melanotan I (afamelanotide, Scenesse) is separately FDA- and EMA-approved, but only for erythropoietic protoporphyria, not for tanning.

PTD-DBM is an investigational research compound; it is not approved by the FDA or any major regulator for any indication, and it is not in marketed dermatologic products. It is not a WADA-listed substance, and the published work remains preclinical with no registered human clinical program for the peptide itself.